• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MICRO THERAPEUTICS, INC. DBA EV3 PIPELINE; INTRACRANIAL ANEURYSM FLOW DIVERTER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MICRO THERAPEUTICS, INC. DBA EV3 PIPELINE; INTRACRANIAL ANEURYSM FLOW DIVERTER Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Ischemia (1942); Thrombosis (2100); Vasoconstriction (2126)
Event Type  Injury  
Manufacturer Narrative
Based on the reported information, there is no evidence suggesting that the device was defective, but rather a post procedure related event.Since the device was not returned, we are unable to perform further root cause analysis.All devices are 100% tested and all products are 100% inspected for damages and irregularities during manufacture.The reported adverse events are known inherent risk of endovascular procedure and are documented in our device¿s instruction for use (ifu).Linked mdr: 2029214-2019-00710.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Medtronic received the following report through literature review of ¿flow diversion covering the m1 origin as a last resort¿ (li-mei lin, matthew t bender, geoffrey p colby, bowen jiang, jessica k campos, david a zarrin, robert w c young, risheng xu, justin m caplan, judy huang, rafael j tamargo, alexander l coon) most patients were female (7/9, 78%) and most aneurysms were right-sided (78%).A single pipeline embolization device (ped) device was used in all cases and adjunctive coiling was performed in four cases (44%).Intra-arterial verapamil was administered for spasmolysis in one case (11%), balloon angioplasty was not performed (0%) and platelet aggregation along the stent was observed in three cases (33%).Two of these were observed intra procedurally and resolved with abciximab administration.One patient (case 5) awoke with aphasia and hemiparesis; immediate dsa demonstrated platelet plugging at the orifice of the covered m1 which resolved with intra-arterial abciximab and complete resolution of clinical deficits.Two patients (22%) experienced complications resulting in permanent neurological deficit, including one major stroke that led to mortality (11%)and one minor stroke (11%).Case 6 was a cinquagenarian smoker with 3 mm proximal right a1 aneurysm treated with ped after unsuccessful attempted stent-coiling.The patient received intra-arterial abciximab at procedure end for delayed filling of the covered right mca.The patient had some left upper extremity weakness on awakening, which resolved with blood pressure augmentation.On postoperative day one in the intensive care unit, the patient developed left upper extremity weakness after an episode of vasovagal hypotension that occurred during removal of the femoral sheath.Mri showed scattered mca territory ischaemia and the patient was mrs 2 at last follow-up.Patients were followed clinically for an average of 27 months.Follow-up dsa showed complete aneurysm occlusion in 7/8 cases (88%) at an average interval of 21 months.Follow-up dsa was performed in all living patients at 6 months, 88% at 12 months and 50% at 24 months.The covered mca showed no delay or minimal delay (arterial phase filling) in 50% of cases (case 4), moderate delay with primarily anterograde flow in 25% of cases (case 5) and significant delay (reliance primarily on aca and external carotid artery (eca) collaterals) in 25% (case 1).No complications were observed beyond the initial 48 hours following embolization over 27 months of clinical follow-up, even with diminution of the mca and reliance on collateral supply from the aca or eca in half of cases.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PIPELINE
Type of Device
INTRACRANIAL ANEURYSM FLOW DIVERTER
Manufacturer (Section D)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA
Manufacturer (Section G)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA
Manufacturer Contact
katcha taylor
9775 toledo way
irvine, CA 92618
7635263305
MDR Report Key8776415
MDR Text Key150573740
Report Number2029214-2019-00711
Device Sequence Number1
Product Code OUT
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional,literatur
Reporter Occupation Physician
Type of Report Initial
Report Date 07/10/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 06/13/2019
Initial Date FDA Received07/10/2019
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-